Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Front and center of this is Novo Nordisk (NYSE: NVO), the once-obscure Danish company that earned the first U.S. Food and Drug Administration (FDA) approval for such treatments with its Wegovy ...

A consumer watchdog group is challenging Sinclair's latest TV station sale, citing concerns about the broadcaster's past regulatory issues. A consumer watchdog organization has challenged Sinclair ...

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth ...

Novo Nordisk A/S slumped amid concern that a weight-loss pill from rival Eli Lilly & Co. will steal market share from bestsellers such as its injected blockbuster Ozempic. The stock dropped as much as ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

BMO analyst says Lilly's update will weigh on shares of Novo Nordisk. The investment firm slashed its price target on NVO shares to $64. Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more ...

The move comes less than a week after Novo’s largest rival, American company Eli Lilly, announced successful clinical trial results for its new oral diabetes medication, which also had ...

$ 60.79-1.84-2.94% ...

Trulicity has been stealing market share from Novo's GLP-1 Victoza (liraglutide). The first trial, PIONEER 4, set the new drug against Novo’s own product, injectable once a week Victoza.